Mantle cell lymphoma (MCL) is an intermediate-grade B-cell lymphoma, representing 2.8% of all non-Hodgkin lymphomas in the US. It is associated with t(11;14)(q13; q23), which leads to the overexpression of cyclin D1, consequently promoting cell proliferation. MCL usually expresses CD19, CD20, CD43, surface immunoglobulins, FMC7, BCL2, cyclin D1, CD5, and SOX11. Herein is a case of a 67-year-old male, referred to our facility with shortness of breath, anemia (hemoglobin of 5.3 g/dL), thrombocytopenia (12 × 10/L), and leukocytosis (283 × 10/L). A peripheral blood smear showed marked lymphocytosis with blastoid morphology. Morphologic examination of the bone marrow biopsy revealed a diffuse sheet of blastoid cells expressing CD20 and CD10, but without CD5 or cyclin D1. Given these features, a differential diagnosis of diffuse large B-cell lymphoma (DLBCL) with germinal center derivation, high-grade follicular lymphoma, and Burkitt lymphoma was considered, with the latter not favored due to morphology. Additional studies revealed positive SOX11, and fluorescence in situ hybridization (FISH) studies detected t(11;14). These additional studies supported diagnosis of the blastoid variant of MCL. In conclusion, we present a unique and challenging case of MCL without cyclin D1 or CD5, but with an expression of CD10 and SOX11, along with t(11;14). Pathologists should explicitly consider the blastoid variant of MCL when dealing with mature B-cell neoplasms with blastoid morphology in adults, and utilize a broad panel of ancillary studies, including FISH and SOX11.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594516PMC
http://dx.doi.org/10.3390/hematolrep15040061DOI Listing

Publication Analysis

Top Keywords

blastoid morphology
12
mantle cell
8
cell lymphoma
8
b-cell lymphoma
8
cyclin cd5
8
additional studies
8
blastoid variant
8
variant mcl
8
lymphoma
6
blastoid
6

Similar Publications

Objectives: High-grade B-cell lymphoma (HGBL), introduced in the 2016 World Health Organization (WHO) revised fourth edition classification, included cases defined by MYC and BCL2 and/or BCL6 rearrangements or by high-grade morphology. Diagnostic criteria and nomenclature for these lymphomas were refined in the 2022 WHO fifth edition (WHO-5) classification and International Consensus Classification (ICC). This review describes our approach to the diagnosis of HGBL.

View Article and Find Full Text PDF

Current Status of Synthetic Mammalian Embryo Models.

Int J Mol Sci

November 2024

Laboratory of Molecular Diagnostics and Cell Biology, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Republic of Korea.

Article Synopsis
  • * Research on these models, including comparisons across species such as mice, humans, and ungulates (pigs and cattle), enhances our knowledge of both unique and shared developmental mechanisms.
  • * The review highlights recent progress in stem cell technology and synthetic embryo models, emphasizing their role in advancing regenerative medicine and improving our understanding of species-specific developmental biology.
View Article and Find Full Text PDF

A rapid progression from classical mantle cell lymphoma to a blastoid variant.

Leuk Res Rep

November 2024

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'hématologie biologique, Pierre-Bénite, France.

This case report presents an 82-year-old male initially diagnosed with classical mantle cell lymphoma (MCL) that progressed to the aggressive blastoid variant. The patient was initially treated with oral chemotherapy (PEP-C), followed by ibrutinib, but experienced disease progression with central nervous system (CNS) involvement and blastoid morphology. Despite subsequent intensive treatment, including high-dose cytarabine (Cytarabine), rituximab, and intrathecal methotrexate (Methotrexate), the patient's disease continued to advance, resulting in death.

View Article and Find Full Text PDF

Mantle cell lymphoma (MCL) is a clinically heterogeneous B-cell neoplasm with unique clinicopathological features, accounting for 5% of all non-Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes.

View Article and Find Full Text PDF

Nuclear receptor-SINE B1 network modulates expanded pluripotency in blastoids and blastocysts.

Nat Commun

November 2024

Cell Fate Engineering and Therapeutics Lab, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Proteos, Singapore, 138673, Republic of Singapore.

Article Synopsis
  • Embryonic stem cells can self-organize into structures similar to blastocysts, which are important for studying early development and potential therapies.
  • Researchers identified key factors influencing blastoid formation, focusing on the gene Nr1h2, which is critical for its development and operation across multiple species.
  • Activation of Nr1h2 not only promotes blastoid creation but also enhances their ability to implant in the uterus and contribute to both embryonic and extraembryonic tissues, highlighting its broad regulatory role in early embryonic development.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!